Bloomberg L.P.9d
BioNTech Beats Expectations, Gives Update on Cancer Drugs
BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88 ...
Benzinga.com7d
Breaking Down BioNTech: 16 Analysts Share Their Views
16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
SWR9d
BioNTech steigert Umsatz mit angepassten Corona-Impfstoffen
Das Mainzer Pharmaunternehmen BioNTech konnte im dritten Quartal seinen Umsatz wieder steigern. Im Zeitraum zwischen Juli und September lag der Umsatz bei rund 1,2 Milliarden Euro. Im ...
4investors22h
BioNTech investiert weiter stark in Onkologie-Pipeline
Auf einen Blick zu BioNTech: - Umsatz in den ersten 9 Monaten 2024 bei 1,56 Milliarden Euro - Nettoverlust von 924,8 Millionen Euro, bedingt durch hohe F&E-Kosten - Umsatzprognose für 2024 am ...
Nasdaq5d
What Analysts Are Saying About BioNTech Stock
Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...
Business Insider10d
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the ...
Benzinga.com4d
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...
FierceBiotech26d
BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...
Reuters10d
BioNTech SE
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
Seeking Alpha26d
BioNTech and Moderna: A tale of two mRNA developers
In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...
Nasdaq9d
BioNTech Q3 Net Profit Rises; Backs FY24 Revenue Outlook Range, But At The Low End
(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net profit of 198.1 million euros or 0.81 euros per share for the third quarter ...